Director at STAAR Surgical (STAA) receives grant of 7,524 stock options

Rhea-AI Filing Summary

STAAR Surgical director Christopher Min Fang Wang received a grant of stock options covering 7,524 shares of common stock. The options have an exercise price of $18.46 per share and expire on March 5, 2036. They vest in full on the earlier of June 18, 2026 or the company’s 2026 annual shareholder meeting.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Wang Christopher Min Fang

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock Option	7,524	$0.00	--

Holdings After Transaction: Common Stock Option — 7,524 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wang Christopher Min Fang

(Last) (First) (Middle)

UNIT 3703, 37/F AIA TOWER

183 ELECTRIC ROAD, NORTH POINT

(Street)

HONG KONG K3 00000

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
STAAR SURGICAL CO [ STAA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock Option	$18.46	03/06/2026		A		7,524		(1)	03/05/2036	Common Stock, par value $0.01 per share	7,524	$0	7,524	D

Explanation of Responses:

1. Award of stock options granted to the Reporting Person on March 6, 2026. These stock options will vest in full on the earlier of June 18, 2026 or the Issuer's 2026 annual meeting of shareholders.

	/s/ Christopher Min Fang Wang	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did STAAR Surgical (STAA) report for Christopher Min Fang Wang?

STAAR Surgical reported that director Christopher Min Fang Wang received a grant of stock options covering 7,524 shares. This is a compensation-related award, not an open-market stock purchase or sale, and is documented in a Form 4 insider transaction filing.

What are the key terms of Christopher Min Fang Wang’s new STAAR Surgical stock options?

The granted options cover 7,524 shares with an exercise price of $18.46 and expire on March 5, 2036. These terms define the cost to exercise the options and the timeframe during which they can be exercised.

When do Christopher Min Fang Wang’s STAAR Surgical options vest?

The options vest in full on the earlier of June 18, 2026 or STAAR Surgical’s 2026 annual meeting of shareholders. Full vesting means all 7,524 options become exercisable at once rather than in installments over several years.

Is the STAAR Surgical Form 4 for Christopher Min Fang Wang a stock purchase or sale?

The Form 4 reflects a grant of stock options as compensation, not a market trade. The transaction is classified as an acquisition via grant or award and does not involve buying or selling shares on the open market.

How many STAAR Surgical options does Christopher Min Fang Wang hold after this grant?

Following this transaction, the filing shows Christopher Min Fang Wang holding 7,524 stock options directly. This matches the size of the award, indicating the Form 4 records this new option position created by the grant.

Does the STAAR Surgical Form 4 mention any special conditions on Wang’s stock options?

Yes. The footnote explains the options were granted on March 6, 2026 and will vest in full on the earlier of June 18, 2026 or the 2026 annual shareholder meeting, tying vesting to a specific date or corporate event.